Jorn Drappa
Chief Medical Officer & Head of Research and DevelopmentDr. Jorn Drappa, M.D. & Ph.D. serves as the Chief Medical Officer at Alumis Inc. since August 2022 and as its Head of Research and Development since September 2022. He has healthcare and pharmaceutical industry experience, having led the advancement of dozens of early to late-stage drug development programs for autoimmune disorders. He is Independent Director of Alpine Immune Sciences, Inc. from July 2022. He was Chief Medical Officer of Ventyx Biosciences, Inc. since September 2021 until May 2022. He served as Executive Vice President of Research and Development and Site Head of Gaithersburg at Horizon Therapeutics Public Limited Company since March 2021 until September 2021. He joined Horizon in March 2021. Dr. Drappa served as an Executive Vice President of Research & Development at Viela Bio, Inc. since March 2021 until March 15, 2021 and served as its Chief Medical Officer and Head of Research and Development since February 2018 until March 2021. Prior to Ventyx, Dr. Drappa co-founded Viela Bio and served as its Head of R&D and Chief Medical Officer through its acquisition by Horizon Therapeutics in March 2021. At Viela Bio, Dr. Drappa led the development of UPLIZNA (inebilizumab-cdon) in multiple indications, culminating in its approval for the treatment of neuromyelitis optica spectrum disorder. Dr. Drappa has experience in research and development in the inflammation and autoimmune therapeutic areas. Dr. Drappa served in various roles of increasing responsibility at MedImmune, the biologics division of AstraZeneca since March 2011, including Vice President, Clinical Development, where he Headed the clinical functions of Respiratory, Inflammation, Autoimmune, Cardiovascular, Metabolic disease and Infectious disease. Previously, Dr. Drappa served as Senior Medical Director for the Inflammation and Autoimmune assets at Genentech from August 2008 to May 2011. Prior to Genentech, Dr. Drappa served as Associate Medical Director at Amgen from March 2003 to March 2006. He held various roles of increasing responsibility leading clinical development programs at Roche. Dr. Drappa received his M. D. and Ph. D. in Medicine from the University of Cologne in 1991 and completed postdoctoral studies in immunology at Cornell University from 1993 to 1996. He completed postdoctoral studies in immunology at Cornell University from 1993 to 1996. He followed by residency in internal medicine at New York Presbyterian Hospital and Rheumatology fellowship at the Hospital for Special Surgery in New York.
公司職務
- 公司名稱Alumis Inc.股票代碼ALMS職務Chief Medical Officer & Head of Research and Development共事同僚
- MBMartin BablerPresident, CEO & Chairman
- DMDavid M. GoldsteinChief Scientific Officer
- JRJohn R. SchroerChief Financial Officer
- SPSanam PangaliChief Legal Officer & Corporate Secretary
- ABAlan B. ColowickIndependent Director
- SSSapna SrivastavaLead Independent Director
- CPC. Patrick MachadoIndependent Director
- JBJames Bruce TananbaumIndependent Director
